Quotes 5-day view Delayed Nyse
01/13/2021
01/14/2021
01/15/2021
01/19/2021
01/20/2021
Date
112.45(c)
111.63(c)
110.52(c)
112.18(c)
112.62(c)
Last
9 821 321
8 268 761
9 196 450
7 723 822
6 554 574
Volume
+2.43% -0.73% -0.99% +1.50% +0.39% Change
Sales 2020
45 636 M - -
Net income 2020
12 355 M - -
Net Debt 2020
75 457 M - -
P/E ratio 2020
27,5x
Yield 2020
4,23%
Sales 2021
53 991 M - -
Net income 2021
17 540 M - -
Net Debt 2021
63 358 M - -
P/E ratio 2021
13,3x
Yield 2021
4,58%
Capitalization
199 B 199 B -
EV / Sales 2020
6,01x
EV / Sales 2021
4,86x
Nbr of Employees
47 000
Free-Float
98,5%
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany...
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
All news about ABBVIE INC.
News in other languages on ABBVIE INC.
Analyst Recommendations on ABBVIE INC.
Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ABBVIE INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
22
Average target price
115,91 $
Last Close Price
112,62 $
Spread / Highest target
19,9%
Spread / Average Target
2,92%
Spread / Lowest Target
-13,9%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
